AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19135798 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (two different clinically relevant doses)
Number of subjects: 36
Study 19135798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17303791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium treatment (400 microg of chromium daily in the form of chromium yeast)
Number of subjects: 0
Study 17303791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15519185 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone, 5 mg/kg body weight
Number of subjects: 36
Study 15519185 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone, 10 mg/kg body weight
Number of subjects: 36
Study 15519185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 36
Study 11300234 — intervention group
Group type: EXPERIMENTAL
Intervention: Six months of progressive whole‐body resistive training (RT)
Number of subjects: 18
Study 9021814 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified beta-thalassemia alleles
Number of subjects: 54
Study 9021814 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of iron overload
Number of subjects: 54
Study 7931889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 micrograms once daily for 4 weeks
Number of subjects: 249
Study 7931889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 100 micrograms once daily for 4 weeks
Number of subjects: 249
Study 7931889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 7931889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (both dosages)
Number of subjects: 249
Study 7931889 — intervention group
Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 249
Study 3076051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy (pure sodium fluoride powder, Ossin, Koreberon)
Number of subjects: 158
Study 3076051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy (Koreberon)
Number of subjects: 158
Study 3076051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy
Number of subjects: 158
Study 31515154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus carboplatin
Number of subjects: 160
Study 31515154 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 160
Study 28507057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus Simvastatin
Number of subjects: 18015
Study 28507057 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 18015
Study 25415292 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen
Number of subjects: 0
Study 25415292 — intervention group
Group type: COMPARATOR
Intervention: 3-drug arm
Number of subjects: 0
Study 25415292 — intervention group
Group type: COMPARATOR
Intervention: 4-drug regimen vs 3-drug arm
Number of subjects: 0
Study 23922746 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (12 g over 8 hours)
Number of subjects: 8
Study 23922746 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 20671070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracket removal (T2)
Number of subjects: 24
Study 20671070 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months post-treatment (T3)
Number of subjects: 24
Study 19439881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin lotion (C lotion) twice daily
Number of subjects: 42
Study 19439881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin+0.025% tretinoin lotion once nightly (CT lotion)
Number of subjects: 42
Study 19439881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin+2% salicylic acid lotion twice daily (CS lotion)
Number of subjects: 42
Study 19439881 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all treatments
Number of subjects: 42
Study 16603564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone autografts
Number of subjects: 1512
Study 16603564 — intervention group
Group type: COMPARATOR
Intervention: Hamstring autografts
Number of subjects: 1512
Study 15656050 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (weight loss and positional therapy)
Number of subjects: 0
Study 15656050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0
Study 15656050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement techniques
Number of subjects: 0
Study 15656050 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 15656050 — intervention group
Group type: COMPARATOR
Intervention: CPAP (standard therapy)
Number of subjects: 0
Study 11379377 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 158
Study 11379377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral estrogen (estriol 2 mg daily)
Number of subjects: 158
Study 11379377 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed transdermal estrogen (estradiol 50 micrograms/24 h)
Number of subjects: 158
Study 9519490 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month traditional therapeutic community program
Number of subjects: 628
Study 9519490 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month traditional therapeutic community program
Number of subjects: 628
Study 9519490 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month modified therapeutic community program emphasizing relapse prevention and health education
Number of subjects: 628
Study 9519490 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month modified therapeutic community program emphasizing relapse prevention and health education
Number of subjects: 628
Study 9519490 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month program for those who stayed at least 171 days
Number of subjects: 628
Study 9519490 — intervention group
Group type: COMPARATOR
Intervention: Shorter programs (3-month) for those who dropped out early
Number of subjects: 628
Study 8454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 113
Study 8454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 1 IGT subjects
Number of subjects: 113
Study 8454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline variables (FPG and 2-h plasma glucose)
Number of subjects: 113
Study 8454106 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 1 baseline (90-min plasma glucose)
Number of subjects: 113
Study 3683485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy (doxorubicin combined with cyclophosphamide or cyclophosphamide combined with methotrexate, fluorouracil, and prednisone)
Number of subjects: 0
Study 3683485 — intervention group
Group type: COMPARATOR
Intervention: Intermittent chemotherapy (stopped after three cycles, repeated only with disease progression)
Number of subjects: 0
Study 29258028 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based Cognitive Behavioral Therapy)
Number of subjects: 0
Study 29258028 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 28409397 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 55
Study 28409397 — intervention group
Group type: EXPERIMENTAL
Intervention: PIST (Prolonged Intermittent Sprint Training)
Number of subjects: 55
Study 28409397 — intervention group
Group type: COMPARATOR
Intervention: HIIT
Number of subjects: 55
Study 28409397 — intervention group
Group type: COMPARATOR
Intervention: CTRL (Sedentary Control Group)
Number of subjects: 55
Study 23852077 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal diclofenac patches
Number of subjects: 40
Study 23852077 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 40
Study 23294179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen of glucosamine and low-dose cyclosporin A (C)
Number of subjects: 12
Study 23294179 — intervention group
Group type: COMPARATOR
Intervention: Single regimen of low-dose cyclosporin A (S)
Number of subjects: 12
Study 21924715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal varicocelectomy with ligation of both internal and external spermatic veins
Number of subjects: 74
Study 21924715 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal varicocelectomy (ligation of internal spermatic vein)
Number of subjects: 74
Study 21924715 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 74
Study 17096678 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg, single subcutaneous or intramuscular injection)
Number of subjects: 228
Study 17096678 — intervention group
Group type: COMPARATOR
Intervention: Degarelix (120-320 mg, multiple subcutaneous doses)
Number of subjects: 228
Study 15366325 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane 60 mg b.i.d. for 4 weeks
Number of subjects: 16
Study 15366325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11451623 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day raloxifene
Number of subjects: 390
Study 11451623 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day raloxifene
Number of subjects: 390
Study 11451623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 390
Study 11451623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 11451623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 390
Study 9530841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical activation during prerecognition processing
Number of subjects: 0
Study 9530841 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken word recognition
Number of subjects: 0
Study 9530841 — intervention group
Group type: EXPERIMENTAL
Intervention: Preregognition lexical processing
Number of subjects: 0
Study 8052956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg
Number of subjects: 23
Study 8052956 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) 50 micrograms/24h
Number of subjects: 23
Study 2929976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 51
Study 2929976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31590390 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 34
Study 31590390 — intervention group
Group type: COMPARATOR
Intervention: Ischemic compression technique (ICT)
Number of subjects: 34
Study 30078280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.01 mg/kg)
Number of subjects: 100
Study 30078280 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 100
Study 27082036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component influenza and Tdap vaccine promotion package
Number of subjects: 325
Study 27082036 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study 24119385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator interval approach
Number of subjects: 100
Study 24119385 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 100
Study 21659896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 20
Study 21659896 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy)
Number of subjects: 20
Study 21659896 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic tendons
Number of subjects: 20
Study 20190833 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD13 Abs
Number of subjects: 0
Study 20190833 — intervention group
Group type: COMPARATOR
Intervention: Soluble CD13
Number of subjects: 0
Study 17279853 — intervention group
Group type: EXPERIMENTAL
Intervention: Values of high perceived cultural importance
Number of subjects: 0
Study 17279853 — intervention group
Group type: COMPARATOR
Intervention: Values of high actual self-importance
Number of subjects: 0
Study 16571709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking ads focusing on young victims suffering from serious tobacco-related diseases
Number of subjects: 1725
Study 16571709 — intervention group
Group type: COMPARATOR
Intervention: Counterindustry and industry ads
Number of subjects: 1725
Study 14675952 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical access therapy
Number of subjects: 0
Study 14675952 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of metronidazole as an adjunct to mechanical treatment
Number of subjects: 0
Study 14675952 — intervention group
Group type: COMPARATOR
Intervention: Mechanical treatment
Number of subjects: 0
Study 10527711 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml liquid cartilage extract
Number of subjects: 29
Study 10527711 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 ml liquid cartilage extract
Number of subjects: 29
Study 10527711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8968711 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized presentation condition
Number of subjects: 0
Study 8968711 — intervention group
Group type: COMPARATOR
Intervention: Unorganized presentation condition
Number of subjects: 0
Study 1677063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg per day)
Number of subjects: 33
Study 1677063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1677063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 33
Study 6223289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 micrograms fenoterol hydrobromide and 80 micrograms ipratropium bromide
Number of subjects: 9
Study 6223289 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms fenoterol + placebo
Number of subjects: 9
Study 6223289 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms fenoterol + placebo
Number of subjects: 9
Study 30826256 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application (MyFitnessPal©)
Number of subjects: 56
Study 30826256 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard post-operative monitoring)
Number of subjects: 56
Study 29018100 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume-guided ultrafiltration biofeedback
Number of subjects: 35
Study 29018100 — intervention group
Group type: COMPARATOR
Intervention: Best clinical practice hemodialysis (control)
Number of subjects: 35
Study 26787637 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (TCI)
Number of subjects: 18
Study 26787637 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI)
Number of subjects: 18
Study 24817188 — intervention group
Group type: COMPARATOR
Intervention: Continuous theta-burst stimulation (Group A)
Number of subjects: 60
Study 24817188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (Group B)
Number of subjects: 60
Study 24817188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of continuous and intermittent theta-burst stimulation (Group C)
Number of subjects: 60
Study 24817188 — intervention group
Group type: COMPARATOR
Intervention: Sham theta-burst stimulation (Group D)
Number of subjects: 60
Study 23010558 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6370 20 mg
Number of subjects: 16
Study 23010558 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6370 60 mg
Number of subjects: 16
Study 23010558 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6370 180 mg
Number of subjects: 16
Study 23010558 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6370 (180 mg total dose in one, two or four divided doses)
Number of subjects: 16
Study 23010558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19281330 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 15 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Number of subjects: 402
Study 19281330 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine
Number of subjects: 402
Study 19281330 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of 10 microg of inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine (14 days apart)
Number of subjects: 402
Study 17616777 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG Pro12Ala variant
Number of subjects: 84
Study 17616777 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG T1431 allele
Number of subjects: 84
Study 17616777 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB3 Trp64Arg variant
Number of subjects: 84
Study 17616777 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB3 Arg64 allele
Number of subjects: 84
Study 15976780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 10500
Study 15976780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10500
Study 12471297 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE+high‐intensity PT
Number of subjects: 80
Study 12471297 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE+PT (combined moderate and high-intensity PT)
Number of subjects: 80
Study 12471297 — intervention group
Group type: COMPARATOR
Intervention: LSE-alone
Number of subjects: 80
Study 10450538 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dihydroartemisinin
Number of subjects: 10
Study 10450538 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine
Number of subjects: 10
Study 10450538 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dihydroartemisinin with 750 mg mefloquine
Number of subjects: 10
Study 7761739 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg) added to decaffeinated coffee at 2220 and 0120 hours for the first 3 nights.
Number of subjects: 30
Study 7761739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given on nights 4 and 5).
Number of subjects: 30
Study 7761739 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and Placebo (both groups received placebo on nights 4 and 5).
Number of subjects: 30
Study 7761739 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and Placebo (during the SALT task).
Number of subjects: 30
Study 2143266 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (5 mg daily; 2.5 mg for children under 20 kg)
Number of subjects: 31
Study 2143266 — intervention group
Group type: COMPARATOR
Intervention: Dexchlorpheniramine (1 mg every 8 hours; 0.5 mg for the youngest children)
Number of subjects: 31
Study 2143266 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical assessment for both drugs
Number of subjects: 31
Study 2143266 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine and dexchlorpheniramine
Number of subjects: 31
Study 7262454 — intervention group
Group type: EXPERIMENTAL
Intervention: pHresh 3.5
Number of subjects: 0
Study 31999300 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 394
Study 31999300 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg intravitreous injections)
Number of subjects: 394
Study 31999300 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (after censoring VF results after PRP treatments)
Number of subjects: 394
Study 31999300 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (initial PRP session)
Number of subjects: 394
Study 31999300 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (additional PRP sessions)
Number of subjects: 394
Study 31999300 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (endolaser)
Number of subjects: 394
Study 31999300 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab injections
Number of subjects: 394
Study 30172451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg daily for 12 weeks
Number of subjects: 242
Study 30172451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg daily for 4 weeks + 50 mg daily for 8 weeks
Number of subjects: 242
Study 30172451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg for 4 weeks followed by 50 mg for 8 weeks
Number of subjects: 242
Study 27487526 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 0
Study 27487526 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg once daily)
Number of subjects: 0
Study 27487526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26362051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal™ (TM) spacers as standalone (SA) devices
Number of subjects: 80
Study 26362051 — intervention group
Group type: COMPARATOR
Intervention: Trabecular Metal™ (TM) spacers with pedicle screw fixation (PF)
Number of subjects: 80
Study 23954724 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 94
Study 23954724 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 94
Study 21907317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 2314
Study 21907317 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2314
Study 18466654 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI and high GL (H-H)
Number of subjects: 8
Study 18466654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI and low GL (L-L)
Number of subjects: 8
Study 18466654 — intervention group
Group type: COMPARATOR
Intervention: High GI and low GL (H-L)
Number of subjects: 8
Study 17157112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 353
Study 17157112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 14563793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstretchable silk tape
Number of subjects: 99